Compare MQ & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MQ | RAPP |
|---|---|---|
| Founded | 2010 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2021 | 2024 |
| Metric | MQ | RAPP |
|---|---|---|
| Price | $18.20 | $26.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 16 |
| Target Price | $20.78 | ★ $64.21 |
| AVG Volume (30 Days) | 708.4K | ★ 1.4M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $624,884,000.00 | N/A |
| Revenue This Year | $11.69 | N/A |
| Revenue Next Year | $12.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.25 | N/A |
| 52 Week Low | $3.70 | $22.06 |
| 52 Week High | $19.40 | $52.93 |
| Indicator | MQ | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 44.08 |
| Support Level | $16.74 | $22.51 |
| Resistance Level | $19.01 | $31.49 |
| Average True Range (ATR) | 0.66 | 1.80 |
| MACD | -0.10 | 0.61 |
| Stochastic Oscillator | 62.44 | 62.39 |
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.